# US 2022/0033391 A1 · Solid form, crystalline form, and crystal form a of fxr agonist, and preparation method and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033391 A1
- Document ID: US20220033391A1
- Status: Published application
- Kind: A1
- Application number: 17/297,271
- Filed: 2019-11-26
- Published: 2022-02-03
- Earliest claimed: 2018-11-26
- Assignees: Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
- Applicants: Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
- Inventors: Xiaolin Li; Peng Li; Haiying He
- Web page: https://patentgrep.com/patent/US20220033391A1

## CPC

- C07D 413/14: containing three or more hetero rings
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Disclosed are a solid form, a crystalline form, and crystal form A of a compound of formula (I) used as an FXR agonist, and a preparation method therefor. Also comprised is an application of the compound of formula (I) in preparation of a medication for treating nonalcoholic steatohepatitis (NASH).

## Claims

### Claim 1

A solid form of a compound of formula (I)

### Claim 2 (depends on 1)

The solid form of a compound of formula (I) according to claim 1, wherein the solid form is a crystalline form.

### Claim 3 (depends on 2)

The crystalline form of the compound of formula (I) according to claim 2, which is crystal form A, characterized by X-ray powder diffraction pattern with characteristic diffraction peaks at the following 2θ angles of 12.72±0.2°, and 25.27±0.2°.

### Claim 4 (depends on 3)

The crystal form A of the compound of formula (I) according to claim 3, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles of 11.86±0.2°, 12.72±0.2°, 16.15±0.2°, 17.40±0.2°, 19.72±0.2°, 24.18±0.2°, and 25.27±0.2°.

### Claim 5 (depends on 4)

The crystal form A of the compound of formula (I) according to claim 4, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles of 11.86±0.2°, 12.72±0.2°, 16.15±0.2°, 17.40±0.2°, 19.72±0.2°, 20.38±0.2°, 22.60±0.2°, 23.80±0.2°, 24.18±0.2°, and 25.27±0.2°.

### Claim 6 (depends on 5)

The crystal form A of the compound of formula (I) according to claim 5, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles of 11.86±0.2°, 12.72±0.2°, 13.67±0.2°, 16.15±0.2°, 17.40±0.2°, 19.72±0.2°, 20.38±0.2°, 22.60±0.2°, 23.80±0.2°, 24.18±0.2°, 25.27±0.2°, and 26.57±0.2°.

### Claim 7 (depends on 6)

The crystal form A of the compound of formula (I) according to claim 6, wherein the XRPD pattern is as shown in FIG. 1.

### Claim 8 (depends on 3)

The crystal form A of the compound of formula (I) according to claim 3, wherein the XRPD pattern is as shown in FIG. 5.

### Claim 9 (depends on 3)

The crystal form A of the compound of formula (I) according to claim 3, characterized by a differential scanning calorimetry curve having a starting point of the endothermic peak at 223.58° C.±3° C.

### Claim 10 (depends on 9)

The crystal form A of the compound of formula (I) according to claim 9, wherein the DSC curve is as shown in FIG. 2.

### Claim 11 (depends on 3)

The crystal form A of the compound of formula (I) according to claim 3, characterized by a thermogravimetric analysis curve having a weight loss of up to 0.7427%±0.2% at 111.29° C.±3° C. and up to 3.6977%±0.2% at 202.79° C.±3° C.

### Claim 12 (depends on 11)

The crystal form A of the compound of formula (I) according to claim 11, wherein the TGA curve is as shown in FIG. 3.

### Claim 13 (depends on 3)

A method for preparing the crystal form A of the compound of formula (I) according to claim 3, comprising:
(a) adding the compound of formula (I) to a solvent;
(b) stirring at 30 to 50° C. for 40 to 55 hours; and
(c) centrifugating, and then volatilizing the solvent to give the crystal form A of the compound of formula (I);
wherein the solvent is alcohol, tetrahydrofuran, water, acetone, acetonitrile, ethyl acetate, a mixed solvent of alcohol and water, or a mixed solvent of acetone and water.

### Claim 14 (depends on 13)

The preparation method according to claim 13, wherein the alcohol is selected from methanol, ethanol, isopropanol and n-propanol.

### Claim 15 (depends on 13)

The preparation method according to claim 13, wherein the solvent is a mixed solvent of alcohol and water, wherein the volume ratio of alcohol to water is 1:0.6 to 1:1.5.

### Claim 16

(canceled)

### Claim 17 (depends on 13)

The preparation method according to claim 13, wherein the solvent is a mixed solvent of acetone and water, wherein the volume ratio of acetone to water is 1:1.5 to 1:2.5.

### Claim 18

(canceled)

### Claim 19

A method for preparing the compound of formula (I), comprising the following steps:
wherein R1 is C1-3 alkyl group.

### Claim 20 (depends on 19)

The preparation method of the compound of formula (I) according to claim 19, comprising the following steps:
wherein
the solvent A is DMF;
the base B is potassium phosphate;
the solvent C is toluene;
the base D is cesium carbonate;
the catalyst E is tris(dibenzylideneacetone)dipalladium;
the ligand F is 2,2-bis(diphenylphosphino)-1,1-binaphthyl;
the solvent G is tetrahydrofuran; and
the base H is sodium hydroxide.

### Claim 21 (depends on 20)

The preparation method of the compound of formula (I) according to claim 20, wherein the volume:mass ratio of the solvent C to the intermediate c is 10:1, the molar ratio of the base D to the intermediate c is 2:1, the molar ratio of the catalyst E to the intermediate c is 0.025:1, and the molar ratio of the ligand F to the intermediate c is 0.05:1.

### Claim 22

A compound represented by formula e, or a pharmaceutically acceptable salt thereof,
wherein R1 is C1-3 alkyl group.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

A method of treating a FXR-related diseases in a subject, comprising administering to the subject the solid form of the compound of formula (I) according to claim 1.

### Claim 25 (depends on 2)

A method of treating a FXR-related diseases in a subject, comprising administering to the subject the crystalline form of the compound of formula (I) according to claim 2.

### Claim 26 (depends on 3)

A method of treating a FXR-related diseases in a subject, comprising administering to the subject the crystal form A of the compound of formula (I) according to claim 3.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the FXR-related disease is non-alcoholic fatty liver disease.
